A Phase 2 interventional study of ANX007 and Sham comparator in Geographic Atrophy, sponsored by Annexon, Inc.. Completed at 53 sites in 3 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by Annexon, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 131 studies in Geographic Atrophy with a site in United States — 35 open to participants now, 45 under way, 5 of them phase 3. Geographic Atrophy · United States.
Among the 131 studies in Geographic Atrophy with a site in United States, this one is the 32nd largest by enrollment of the 107 interventional ones that give a count, is one of 3 that started in 2021, is one of 43 in phase 2, and was the 77th registered.
188 studies on the registry are indexed under Geographic Atrophy; 52 are open to participants now.
Browse Geographic Atrophy studies →35 of the 131 studies in Geographic Atrophy with a site in United States are open now. Recruiting first, the newest first:
Genentech, Inc. · Sites in United States
Ages 50+
Biojiva LLC · Sites in United States, Australia
Ages 55+
Sitala Bio LTD · Sites in United States, Argentina, Australia and 4 more countries
Ages 60+
University of Utah · Sites in United States
Ages 65–90
Cellio Therapeutics Inc · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 40 Geographic Atrophy studies recruiting now, 31 (78%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
131 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 33 · Phase 2 65 · Phase 3 20
First in 2000; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 270 is above the median of 70 across 141 interventional studies indexed under Geographic Atrophy.
Median enrollment 98 across the 107 interventional studies, 138 across the 24 observational. Of the 79 that completed or were terminated, 40 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
109 of 131 have an industry lead sponsor. The 10 most frequent:
Annexon, Inc. is the lead sponsor of 16 studies on the registry; 2 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 3 (38%) have results posted.
Annexon, Inc. has 3 studies filed under Geographic Atrophy — fewer than ten, so there is no comparison to draw.
12 of the studies in Geographic Atrophy with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05949593Phase 3Belite Bio, IncPhase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy | 2027-06-30 |
| NCT06510816Phase 3Annexon, Inc.A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA) | 2027-07-31 |
| NCT06769048Boehringer IngelheimA Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy | 2026-12-22 |
| NCT07747662University of Wisconsin, MadisonAdaptive Optics Scanning Light Ophthalmoscopy (AOSLO) and Microperimetry (MP) Sub-study | 2027-02 |
| NCT07144137Complement TherapeuticsA Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA) | 2027-03-31 |
Add all 12 to your calendar (.ics) → With an account.
Among the 131 studies in Geographic Atrophy with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is being conducted in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) to determine if intravitreal (IVT) injections of ANX007 reduce GA lesion growth rate. The results will be used to guide further development of ANX007 in participants with geographic atrophy. The total duration of participation is expected to be approximately 19 months.
The criteria were revised on the registry on Oct 21, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Center based on assessment of FAF imaging at screening:
Well-demarcated GA with a total area (baseline lesion size) ≥2.5 millimeter squared (mm\^2) and
The entire GA lesion must be completely visualized on the macula centered image and must be able to be imaged in its entirety and not contiguous with any peripapillary atrophy.
Exclusion Criteria:
Any evidence of choroidal neovascularization (CNV) in the study eye:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ANX007 administered every month
Drug: ANX007
ANX007 administered every other month
Drug: ANX007
Sham injection administered every month
Other: Sham comparator
Sham injection administered every other month
Other: Sham comparator
Form: solution for injection; Route of Administration: IVT
Form and Route of Administration: pressure to mimic IVT injection
Rate of Change (Slope) From Baseline to Month 12 in GA Lesion Area
GA lesion area was assessed by fundus autofluorescence (FAF) imaging, by an independent central reading center for GA lesion area. A linear mixed effect (LME) model was used to analyze the rate of change from baseline to Month 12 GA lesion area (mm2) for all groups. The model included fixed effects of treatment, time point, treatment by time point interaction, baseline GA lesion area, baseline GA lesion area by timepoint interaction, and baseline lesion multifocality. A random intercept for participant ID and a random slope for timepoint are included to account for repeated measurements for participants. The GA lesion area was analyzed as reported (that is, not transformed).
Time frame: Baseline to Month 12
Change From Baseline to Month 12 in GA Lesion Area
GA lesion area was assessed by fundus autofluorescence (FAF) imaging, by an independent central reading center for GA lesion area.
Time frame: Baseline to Month 12
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign (including a clinically significant abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the investigational medicinal product. A summary of serious and all other non-serious adverse events regardless of causality is located in the Reported Adverse events module.
Time frame: Baseline to Month 12
Change From Baseline to Month 12 in Best Corrected Visual Acuity (BCVA)
BCVA was assessed by the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score on a test chart at a starting distance of 4 meters at each study visit. BCVA scores range from 0 to 100 letters with a higher score indicating a better vision.
Time frame: Baseline to Month 12
Number of Events With Confirmed ≥ 15-Letter Loss BCVA Decline
Confirmed ETDRS BCVA ≥15-letter loss was defined as ≥15-letter loss observed for 2 consecutive visits. BCVA was assessed by the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score on a test chart at a starting distance of 4 meters at each study visit. BCVA scores range from 0 to 100 letters with a higher score indicating a better vision.
Time frame: Baseline to Month 12
Change From Baseline to Month 12 in LLVA
LLVA was assessed by the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score on a test chart at a starting distance of 4 meters at each study visit. BCVA scores range from 0 to 100 letters with a higher score indicating a better vision.
Time frame: Baseline to Month 12
Number of Events With ≥ 15-Letter Loss LLVA Decline
LLVA ≥15-letter loss worsening from Baseline during the 12-month Treatment. LLVA was assessed by the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score on a test chart at a starting distance of 4 meters at each study visit. BCVA scores range from 0 to 100 letters with a higher score indicating a better vision.
Time frame: Baseline to Month 12
Change From Baseline to Month 12 in LLVD
LLVD as assessed by the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score on a test chart at a starting distance f 4 meters at each study visit. LL-VD will be derived by subtracting LL-BCVA from BCVA.
Time frame: Baseline to Month 12
Number of Events With ≥ 15-Letter Loss LLVD Decline
LLVD ≥15-letter loss worsening from Baseline during the 12-month Treatment. LLVD was assessed by the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score on a test chart at a starting distance of 4 meters at each study visit. BCVA scores range from 0 to 100 letters with a higher score indicating a better vision.
Time frame: Baseline to Month 12
As prespecified, data were collected and reported for the participants. Therefore, the "N"s reported below = number of participants regardless of which eye was evaluated.
| Milestone | ANX007 EM | ANX007 EOM | Sham |
|---|---|---|---|
| Started | 89 | 92 | 89 |
| Received at least 1 dose of study drug | 89 | 92 | 89 |
| Completed | 73 | 77 | 76 |
| Not completed | 16 | 15 | 13 |
| Withdrew: Adverse event | 4 | 7 | 3 |
| Withdrew: Lost to follow-up | 2 | 2 | 1 |
| Withdrew: Physician decision | 1 | 0 | 1 |
| Withdrew: Protocol violation | 1 | 1 | 0 |
| Withdrew: Withdrawal by subject | 7 | 5 | 6 |
| Withdrew: Other than specified | 1 | 0 | 1 |
| Withdrew: Death | 0 | 0 | 1 |
GA lesion area was assessed by fundus autofluorescence (FAF) imaging, by an independent central reading center for GA lesion area. A linear mixed effect (LME) model was used to analyze the rate of change from baseline to Month 12 GA lesion area (mm2) for all groups. The model included fixed effects of treatment, time point, treatment by time point interaction, baseline GA lesion area, baseline GA lesion area by timepoint interaction, and baseline lesion multifocality. A random intercept for participant ID and a random slope for timepoint are included to account for repeated measurements for participants. The GA lesion area was analyzed as reported (that is, not transformed).
| mm^2/year | ANX007 EM | ANX007 EOM | ANX007 Pooled | Sham |
|---|---|---|---|---|
| Rate of Change (Slope) From Baseline to Month 12 in GA Lesion Area | 1.9902 ± 0.36343 | 2.1575 ± 0.34824 | 2.0837 ± 0.30177 | 1.9019 ± 0.34239 |
GA lesion area was assessed by fundus autofluorescence (FAF) imaging, by an independent central reading center for GA lesion area.
| mm^2 | ANX007 EM | ANX007 EOM | ANX007 Pooled | Sham |
|---|---|---|---|---|
| Change From Baseline to Month 12 in GA Lesion Area | 2.3547 ± 0.26452 | 2.5782 ± 0.24317 | 2.4835 ± 0.18003 | 2.3170 ± 0.23142 |
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign (including a clinically significant abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the investigational medicinal product. A summary of serious and all other non-serious adverse events regardless of causality is located in the Reported Adverse events module.
| Participants | ANX007 EM | ANX007 EOM | Sham |
|---|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) | 65 | 68 | 68 |
BCVA was assessed by the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score on a test chart at a starting distance of 4 meters at each study visit. BCVA scores range from 0 to 100 letters with a higher score indicating a better vision.
| Number of letters read correctly | ANX007 EM | ANX007 EOM | Sham |
|---|---|---|---|
| Change From Baseline to Month 12 in Best Corrected Visual Acuity (BCVA) | -1.7 ± 1.33 | -2.6 ± 1.29 | -4.1 ± 1.31 |
Confirmed ETDRS BCVA ≥15-letter loss was defined as ≥15-letter loss observed for 2 consecutive visits. BCVA was assessed by the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score on a test chart at a starting distance of 4 meters at each study visit. BCVA scores range from 0 to 100 letters with a higher score indicating a better vision.
| Number of Events | ANX007 EM | ANX007 EOM | Sham |
|---|---|---|---|
| Number of Events With Confirmed ≥ 15-Letter Loss BCVA Decline | 4 | 8 | 15 |
LLVA was assessed by the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score on a test chart at a starting distance of 4 meters at each study visit. BCVA scores range from 0 to 100 letters with a higher score indicating a better vision.
| Number of letters read correctly | ANX007 EM | ANX007 EOM | Sham |
|---|---|---|---|
| Change From Baseline to Month 12 in LLVA | -1.4 ± 1.29 | -2.8 ± 1.25 | -4.8 ± 1.31 |
LLVA ≥15-letter loss worsening from Baseline during the 12-month Treatment. LLVA was assessed by the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score on a test chart at a starting distance of 4 meters at each study visit. BCVA scores range from 0 to 100 letters with a higher score indicating a better vision.
| Number of Events | ANX007 EM | ANX007 EOM | Sham |
|---|---|---|---|
| Number of Events With ≥ 15-Letter Loss LLVA Decline | 6 | 8 | 16 |
LLVD as assessed by the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score on a test chart at a starting distance f 4 meters at each study visit. LL-VD will be derived by subtracting LL-BCVA from BCVA.
| Number of letters read correctly | ANX007 EM | ANX007 EOM | Sham |
|---|---|---|---|
| Change From Baseline to Month 12 in LLVD | -0.4 ± 1.55 | 1.3 ± 1.50 | 0.6 ± 1.57 |
LLVD ≥15-letter loss worsening from Baseline during the 12-month Treatment. LLVD was assessed by the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score on a test chart at a starting distance of 4 meters at each study visit. BCVA scores range from 0 to 100 letters with a higher score indicating a better vision.
| Number of Events | ANX007 EM | ANX007 EOM | Sham |
|---|---|---|---|
| Number of Events With ≥ 15-Letter Loss LLVD Decline | 4 | 8 | 13 |
Collected over Up to 12 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ANX007 EM | 2/89 (2.2%) | 21/89 (23.6%) | 21/89 (23.6%) |
| ANX007 EOM | 3/92 (3.3%) | 16/92 (17.4%) | 20/92 (21.7%) |
| Sham | 2/89 (2.2%) | 16/89 (18%) | 23/89 (25.8%) |
| Event | ANX007 EM | ANX007 EOM | Sham |
|---|---|---|---|
| Atrial fibrillationCardiac disorders | 2/89 | 4/92 | 0/89 |
| PneumoniaInfections and infestations | 3/89 | 2/92 | 0/89 |
| Acute myocardial infarctionCardiac disorders | 2/89 | 1/92 | 0/89 |
| Urinary tract infectionInfections and infestations | 1/89 | 1/92 | 2/89 |
| Cerebrovascular accidentNervous system disorders | 2/89 | 0/92 | 2/89 |
| EndophthalmitisInfections and infestations | 1/89 | 2/92 | 0/89 |
| Angina pectorisCardiac disorders | 0/89 | 2/92 | 0/89 |
| Dry age-related macular degenerationEye disorders | 1/89 | 0/92 | 0/89 |
| IritisEye disorders | 1/89 | 0/92 | 0/89 |
| Neovascular age-related macular degenerationEye disorders | 1/89 | 0/92 | 0/89 |
| Event | ANX007 EM | ANX007 EOM | Sham |
|---|---|---|---|
| COVID-19Infections and infestations | 12/89 | 10/92 | 10/89 |
| Urinary tract infectionInfections and infestations | 6/89 | 7/92 | 12/89 |
| Conjunctival haemorrhageEye disorders | 7/89 | 6/92 | 3/89 |
Intent-to-Treat (ITT) population included all randomized participants.
| Age, Continuous(years) | ANX007 EM | ANX007 EOM | Sham | Total |
|---|---|---|---|---|
| Mean | 79.7 ± 8.64 | 80.5 ± 8.53 | 79.8 ± 7.49 | 80.0 ± 8.22 |
| Sex: Female, Male(Participants) | ANX007 EM | ANX007 EOM | Sham | Total |
|---|---|---|---|---|
| Female | 47 | 60 | 59 | 166 |
| Male | 42 | 32 | 30 | 104 |
| Ethnicity (NIH/OMB)(Participants) | ANX007 EM | ANX007 EOM | Sham | Total |
|---|---|---|---|---|
| Hispanic or Latino | 1 | 2 | 3 | 6 |
| Not Hispanic or Latino | 88 | 89 | 86 | 263 |
| Unknown or Not Reported | 0 | 1 | 0 | 1 |
| Race (NIH/OMB)(Participants) | ANX007 EM | ANX007 EOM | Sham | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 1 | 2 | 2 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 0 | 1 |
| Black or African American | 1 | 0 | 0 | 1 |
| White | 87 | 89 | 87 | 263 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Study Eye GA Lesion Size(square millimeters (mm^2)) | ANX007 EM | ANX007 EOM | Sham | Total |
|---|---|---|---|---|
| Mean | 7.2789 ± 3.96342 | 7.5284 ± 4.09946 | 7.2802 ± 3.98783 | 7.3643 ± 4.00505 |
| Best Corrected Visual Acuity (BCVA)(Number of letters read correctly) | ANX007 EM | ANX007 EOM | Sham | Total |
|---|---|---|---|---|
| Mean | 58.8 ± 17.19 | 57.9 ± 15.30 | 58.5 ± 16.23 | 58.4 ± 16.19 |
| Low-Luminance Visual Acuity (LLVA)(Number of letters read correctly) | ANX007 EM | ANX007 EOM | Sham | Total |
|---|---|---|---|---|
| Mean | 35.3 ± 16.41 | 29.6 ± 15.72 | 34.2 ± 18.05 | 33.0 ± 16.86 |
| Low-Luminance Visual Acuity Deficit (LLVD)(Number of letters read correctly) | ANX007 EM | ANX007 EOM | Sham | Total |
|---|---|---|---|---|
| Mean | 23.5 ± 16.08 | 28.3 ± 18.39 | 25.0 ± 15.70 | 25.7 ± 16.86 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2021 to primary completion in Mar 2023, 25 months.
Results were first posted in Oct 2026, 3 years 6 months after primary completion.
Of 24 phase 2 interventional studies under Geographic Atrophy, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 54. This study's 25 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vonaprument
Annexon, Inc.